Decitabine

目录号:S1200 别名: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine是DNA甲基转移酶抑制剂,整合进入DNA、导致DNA低甲基化,并使DNA复制停滞在intra-S-phase。Decitabine被用于治疗骨髓增生异常综合征(MDS)。

规格 价格 库存 购买数量  
RMB 1269.11 现货
RMB 732.42 现货
RMB 1419.77 现货
RMB 2621.82 现货
RMB 4679.47 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献8篇:

客户使用该产品的3个实验数据:

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

产品安全说明书

DNA Methyltransferase抑制剂选择性比较

生物活性

产品描述 Decitabine是DNA甲基转移酶抑制剂,整合进入DNA、导致DNA低甲基化,并使DNA复制停滞在intra-S-phase。Decitabine被用于治疗骨髓增生异常综合征(MDS)。
特性 Decitabine 是DNA甲基化的有效抑制剂。
靶点
DNA methylation [1]
(HL-60, KG1a cells)
体外研究

Decitabine 有效抑制DNA 合成,这种作用存在剂量依赖性,作用于HL-60和 KG1a 白血病细胞时,IC50分别为 100 ng/mL 和1 ng/mL。Decitabine 抑制细胞生长,这种作用存在剂量和时间依赖性,处理HL-60和KG1a白血病细胞72小时和96小时,IC50分别约为100 ng/mL 和 10 ng/mL。[1] 最新研究显示Decitabine作用于间变性大细胞淋巴瘤(ALCL),具有抗增殖和促凋亡活性,且抑制KARPAS-299细胞中[3H]胸甘的摄取,EC50 为0.49 μM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MXXGeY5kfGmxbjDBd5NigQ>? MYqwMlXDqM7:TR?= M1ziPFI1KGh? M1r1S5difGW{ M13u[o1w\HWuYYTld{B1cGViZ3Xu[UBmgHC{ZYPzbY9vKG:oIF3BS2UuSSCvZX3i[ZJ{ NGfmbpAzPTF{M{C4Ni=>
Eca109 NVW0bYs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fyTlAvPS9{LkWvOUDPxE1? NH\uRYUzPC92OD:3NkBp NHTkOXV4[XSnch?= NGXyPVdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NHvCb5kzPTF{M{C4Ni=>
Eca109 M1XjSWZ2dmO2aX;uJGF{e2G7 NFryeIwxNjYEoN88US=> M{jq[FYwOTJxMkSgbC=> Mkjje4F1\XJ? NVrURYpkcW6qaXLpeJMh[2WubDDtbYdz[XSrb39CpC=> NHL4O3ozPTF{M{C4Ni=>
Eca109 NETrSmFHfW6ldHnvckBCe3OjeR?= MVOwMlXDqM7:TR?= NGPBOmMzPCCq MnHre4F1\XJ? MUPpcohq[mm2czDj[YxtKGmwdnHzbY9v MV2yOVEzOzB6Mh?=
Eca109 NX\hSplLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[xNYcxNjYEoN88US=> MVWyOEBp MYr3ZZRmeg>? M2TBOYlv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> NV\O[lRVOjVzMkOwPFI>
Eca109 NFLsdY5HfW6ldHnvckBCe3OjeR?= MYqwMlUwOSEQvF2= MXiyOEBp NHvlVmN4[XSnch?= NVn1PHN2\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= NUS2UppiOjVzMkOwPFI>
SW1116  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWwMlUwOS9{L{Wg{txO NEXiZ5k1QCCq NEnNcZJFVVOR NGDF[4RmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v MUOyOFg4PDJ6Nh?=
LOVO NUH6b5hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HmOVAvPS9zL{KvOUDPxE1? MVK0PEBp NGP6bo5FVVOR MmC4[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> MoDNNlQ5PzR{OE[=
SW1116  M2HYd2Z2dmO2aX;uJGF{e2G7 MlnoNVAh|ryP Mn;pOFghcA>? M4fFOWROW09? M4j1OIlv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? M3joSlI1QDd2Mki2
LOVO M1;YWGZ2dmO2aX;uJGF{e2G7 M2OzUlExKM7:TR?= Ml3rOFghcA>? M16zc2ROW09? MoHabY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MV[yOFg4PDJ6Nh?=
SW1116  NVO4SmZbSXCxcITvd4l{KEG|c3H5 M4nOWVExKM7:TR?= NYHZU4dHPDhiaB?= NUnPNZVUTE2VTx?= MVHlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NICyR4ozPDh5NEK4Oi=>
LOVO NWXBbm9ZSXCxcITvd4l{KEG|c3H5 NHHEdlcyOCEQvF2= Ml6yOFghcA>? M3z1emROW09? Mlj4[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz NFrHVIozPDh5NEK4Oi=>
RPMI-8226 MXzBdI9xfG:|aYOgRZN{[Xl? MmfPNU8zKM7:TR?= NYrlfoo6PDhxN{KvPVYhcA>? NIHBWGtFVVOR NGG0cmJqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NIL1cYczPDh|M{GwPC=>
OPM-2  NFPJOmRCeG:ydH;zbZMhSXO|YYm= NEDC[JEyNzJizszN MYO3Nk86Pi9zMkCgbC=> MWjEUXNQ MlLWbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MXqyOFg{OzFyOB?=
JJN3  NVm5e3ZTSXCxcITvd4l{KEG|c3H5 MnO5NE42NzFizszN NUTDR2Q{OjRxNEigbC=> M2PWcGROW09? M3LnTYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NFTyb3MzPDh|M{GwPC=>
NCI-H929  M1T0[2Fxd3C2b4Ppd{BCe3OjeR?= NWK0epRHOS9{IN88US=> MXS3Nk86Pi9zMkCgbC=> M{HoXmROW09? MYPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MmroNlQ5OzNzMEi=
RPMI-8226 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme2NU8zKM7:TR?= NV[2UI1mOjRxNEivO|IhcA>? MVHEUXNQ NVrUWXp1[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NXnNT4R6OjR6M{OxNFg>
OPM-2  MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPMbWsyNzJizszN MoHLNlQwPDhxN{KgbC=> MkHiSG1UVw>? Ml;aZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NXzNXoREOjR6M{OxNFg>
JJN3  NYn4SVBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPDWpkxNjVxMTFOwG0> Mlz2NlQwPDhxN{KgbC=> M2DhTGROW09? M4LHU4Fn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 Mkm1NlQ5OzNzMEi=
NCI-H929  MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjqNU8zKM7:TR?= MmDyNlQwPDhxN{KgbC=> NHTQbHZFVVOR MXrh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NI\5b3MzPDh|M{GwPC=>
HeLa Mn\1T4lv[XOnIFHzd4F6 NX;mZ5pnU2l;MUCwNQKBmzVyMECg{txOKG[xcjDoSW5VOQ>? M1ezOlI1PzhyMEm4
HeLa NUP5VlRCU2mwYYPlJGF{e2G7 M4PwcGtqRTVwNjFCtUAxNjVizszNJIZweiCqRV7UNi=> MYiyOFc5ODB7OB?=
HeLa M17qVWtqdmG|ZTDBd5NigQ>? NGr5VmVMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy M{HpSlI1PzhyMEm4
HeLa NGf2dWNMcW6jc3WgRZN{[Xl? Mn;TT4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> NYjHUHR7OjR5OECwPVg>
NB4 NXi4b4dVTnWwY4Tpc44hSXO|YYm= NUHPVIhZOi53L{WvO{42NzFyIN88US=> MnLhNlQhcA>? NWDJXZV7TE2VTx?= Mm\tbY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=> NEDuSnMzPDR6NEi3NC=>
CD4+ CD25− T  NHHZcJhHfW6ldHnvckBCe3OjeR?= M3TtblEwPSEQvF2= NFq2WFRz\WS3Y3XTJIdtd2KjbDDEUmEhdWW2aInsZZRqd25? NGXhb5IzPDR5NkO2NC=>
BV-173 Mlz4RZBweHSxc3nzJGF{e2G7 NI\VNooxNjJ3L{CuOU8xNjd3L{Gg{txO M1LORlQ5Nzd{L{m2JIg> M4HmPeKhWEKV NHLDd3RqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NITBOoIzPDR{M{[xNy=>
ML-1 MYnBdI9xfG:|aYOgRZN{[Xl? MWmwMlI2NzBwNT:wMlc2NzFizszN NHLMbYw1QC95Mj:5OkBp NUDGPWpuyqCSQmO= M4LHc4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NWnNUFc4OjR2MkO2NVM>
HL-60 NUDYXlJuSXCxcITvd4l{KEG|c3H5 NHPCWYIxNjJ3L{CuOU8xNjd3L{Gg{txO NEW0NVU1QC95Mj:5OkBp NFnBPZDDqFCEUx?= NVjzN4g6cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M1fobFI1PDJ|NkGz
KG-1a NGD2SlhCeG:ydH;zbZMhSXO|YYm= NXSwb3JyOC5{NT:wMlUwOC55NT:xJO69VQ>? Mnq0OFgwPzJxOU[gbC=> NWOw[mJbyqCSQmO= MWTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MYiyOFQzOzZzMx?=
BV-173 M4W4NmZ2dmO2aX;uJGF{e2G7 NX7yW5lWOjVyL{WwNI5O MWm0PEBp NEDXdYbDqFCEUx?= M2Gwb4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MV6yOFQzOzZzMx?=
CEM MkHpSpVv[3Srb36gRZN{[Xl? MVeyOVAwPTBybl2= MoraOFghcA>? NHm2RZfDqFCEUx?= MkDCbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MU[yOFQzOzZzMx?=
HL-60 MYTGeY5kfGmxbjDBd5NigQ>? MX:yOVAwPTBybl2= MWK0PEBp NVPqRXE2yqCSQmO= MmnvbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M135WFI1PDJ|NkGz
ML-1 MXXGeY5kfGmxbjDBd5NigQ>? M3Sy[lI2OC93MEDuUS=> NWn0TYhRPDhiaB?= NIHRTYLDqFCEUx?= MnHSbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M4HT[FI1PDJ|NkGz
DLD-1 MX7GeY5kfGmxbjDBd5NigQ>? MYSyOVAwPTBybl2= NH3VRYo1QCCq M3LqWeKhWEKV NHW5XIFldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NHOxbHYzPDR{M{[xNy=>
HCT-116 NFGydFdHfW6ldHnvckBCe3OjeR?= NH\Nc|kzPTBxNUCwcm0> M1XaNlQ5KGh? NX3IeYZlyqCSQmO= Mn35[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? NGCxTpEzPDR{M{[xNy=>
U937-A/E-9/14/18  MonJRZBweHSxc3nzJGF{e2G7 MX2wMlAyNzBwMT:xM|ExKM7:TR?= MXe0PEBp MYjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmrMNlQ{ODB2NU[=
HT29 M2XTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTtNW83PzJiaB?= M1LicWlEPTB;MUSwNOKyOTd7IN88US=> MoPMNlQyPzJyNkG=
SW48 NWjLVpZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW3NkBp MV7JR|UxRTF3LkNCtVYvOiEQvF2= M3fBSlI1OTd{ME[x
HCT116 NX75[YxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUC3NkBp M2DWfGlEPTB;MT63xtExNjRizszN MmjYNlQyPzJyNkG=
HepG2 NEHPfGlHfW6ldHnvckBCe3OjeR?= MUiwMlUwOSEQvF2= MlXVNlQhcA>? NHzpcJhFVVOR NWPRe5c3fXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= M33J[VI1OTR4OEe0
LS174T MkTJSpVv[3Srb36gRZN{[Xl? NXTQTnV{OC53L{Gg{txO M4LDXVI1KGh? MYrEUXNQ NHfW[Ylt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> NXv3S|BnOjRzNE[4O|Q>
HepG2 MXfBdI9xfG:|aYOgRZN{[Xl? NWTJOnBiOS9zMD:xNFAh|ryP M2ThUFch\A>? NVL4T|dCTE2VTx?= M4HjW4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFHIRW4zPDF2Nki3OC=>
LS174T NWfxTGNtSXCxcITvd4l{KEG|c3H5 NWXOVItSOS9zMD:xNFAh|ryP MknQO{Bl NV;3UY9oTE2VTx?= Mnf4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NETIUIUzPDF2Nki3OC=>
QBC-939 MVrBdI9xfG:|aYOgRZN{[Xl? M4TvfVEwOTBxMUCwJO69VQ>? NUXaSY9sPyCm M1XySWROW09? M3q4R4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHLkU2UzPDF2Nki3OC=>
U251 NH;ERW5CeG:ydH;zbZMhSXO|YYm= MX:xM|ExNzFyMDFOwG0> MUO3JIQ> NV[yeo42TE2VTx?= MlvZbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3nTb|I1OTR4OEe0
HL-60 NILubmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XmOVEh|ryP MVy0PEBp NH7a[FlqdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?= M33MfVI1ODByM{K0
MDA‑MB‑453 MXPGeY5kfGmxbjDBd5NigQ>? NUfudJF3OC5{L{Gg{txO M3TIR|czKGh? MlnUZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg M2\tOVI{QDR2MkK4
HCC1569 Moj2SpVv[3Srb36gRZN{[Xl? NVSwb2w3OC5{L{Gg{txO M3PPN|czKGh? NUnXdpBz[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh MXiyN|g1PDJ{OB?=
BT‑474 NV\aW3drTnWwY4Tpc44hSXO|YYm= MlvjNE4zNzFizszN NWXQOohCPzJiaB?= NYXoWXps[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh M134WlI{QDR2MkK4
AGS MmjORZBweHSxc3nzJGF{e2G7 Mn\lOU8yOC9{MD:1NEDPxE1? NGO4bZM1QMLiaNMg M3rYOGROW09? M{jRfolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh NHTDe4IzOzV6Mke4OC=>
A549 M{DFfmFxd3C2b4Ppd{BCe3OjeR?= NULJb2N4PS9zMD:yNE82OCEQvF2= NYfuOpFCPDkEoHlCpC=> MkP6SG1UVw>? NIDnSIpqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? NFvNN4YzOzV6Mke4OC=>
AGS  M4Lx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi1VY11PS9zMD:yNE82OCEQvF2= NHnBcZg1QMLiaNMg MVTEUXNQ Mmf5bY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg NInjXmIzOzV6Mke4OC=>
Kasumi-1 MVHBdI9xfG:|aYOgRZN{[Xl? NVTaenh[OC53IN88US=> M1XOSFQ5yqCqwrC= NEPZOmFl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NXLTXY5{OjN2OUOzOFg>
OCI-AML3 Ml;VRZBweHSxc3nzJGF{e2G7 M3XaS|IvPSEQvF2= MnzjOFjDqGkEoB?= M2TDWYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj MmryNlM1QTN|NEi=
MV4-11 MlXQRZBweHSxc3nzJGF{e2G7 Mnf6Nk42KM7:TR?= NEnMTII1QMLiaNMg MnXv[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NV7xSpBEOjN2OUOzOFg>
NK  MWjDfZRwfG:6aYT5JGF{e2G7 NWPxUZJbOC5yMj2yNEDPxE1? NHvMOVk2KGR? NXr3dIRK\GWlcnXhd4V{KHSqZTDjfZRwdHm2aXOgZYN1cX[rdImgc4YhVktiY3XscJMh[XRiaX70[ZJu\WSrYYTlJINwdmOnboTyZZRqd26|IILld5VtfGmwZzDpckBiKFVvc3jhdIVlKGSxc3ZihLNz\XOyb37z[UBkfXK4ZR?= NFniUZozOzN{OEC4PC=>
NK  M4jyUWFxd3C2b4Ppd{BCe3OjeR?= NY\BfWZJOC5yMj2yNEDPxE1? MXy1JIQ> MXLk[YNz\WG|ZTDOT{Bk\WyuIIDyc4xq\mW{YYTpc44h[W6mII\pZYJqdGm2eTDhd{B1cGViY3;uZ4VvfHKjdHnvckBqdmO{ZXHz[YQ> Mn7CNlM{OjhyOEi=
NK  MmXBSpVv[3Srb36gRZN{[Xl? NV\6bY5rOC5yMT2yNEDPxE1? MVy1JIQ> NHuxfI5k[XW|ZYOgbJlxd22ndHj5cIF1cW:wIH;mJG5MKGOnbHzzJIlvKGFiZH;z[gKBm3Knc4DvcpNm NWPtdo5JOjN|MkiwPFg>
MOLT4/DNR NVrhbIRuTnWwY4Tpc44hSXO|YYm= MlXDOUDPxE1? MmnsOEBl MWfy[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> MkS1NlMxPjB3N{C=
Jurkat/DOX NIe5e3NHfW6ldHnvckBCe3OjeR?= NGnONI42KM7:TR?= MUG0JIQ> NYfIeJM6emWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? MXiyN|A3ODV5MB?=
MOLT4/DNR NVHoNmhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TQNVUh|ryP NVzySmI3PCCm MnLYdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= MViyN|A3ODV5MB?=
Jurkat/DOX MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X3VVUh|ryP MYm0JIQ> NEXCdWhz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 MWmyN|A3ODV5MB?=
ccRCC  MXHBdI9xfG:|aYOgRZN{[Xl? NVjrUWYyOC5yMT2xNO69VQ>? NXHtTpp1PzJiaB?= Mnf4SG1UVw>? MnXNbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? NF;zVIYzOjh{NkS2Oy=>
TNBC  Mn3mRZBweHSxc3nzJGF{e2G7 M4TtSlAvODFvMUFOwG0> M2TBUlczKGh? M{\CR2ROW09? NYrQb4xGcGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= MXWyNlgzPjR4Nx?=
A498 M2D5fGFxd3C2b4Ppd{BCe3OjeR?= NFTqS|UxNjBzLUGw{txO NIrkUZg4OiCq NHvoOWVFVVOR NFHK[VhqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv M{PnXVIzQDJ4NE[3
KIJ265T MkTPRZBweHSxc3nzJGF{e2G7 M{\mR|AvODFvMUFOwG0> NVH2WlV{PzJiaB?= MWfEUXNQ NGTh[W9qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NV3U[ZJUOjJ6Mk[0Olc>
MDA-231 NIrWO41CeG:ydH;zbZMhSXO|YYm= M4TMZVAvODFvMUFOwG0> M2L6UlczKGh? NEjtboFFVVOR M1TVOIlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MVGyNlgzPjR4Nx?=
BT-20 Mnr3RZBweHSxc3nzJGF{e2G7 MkPWNE4xOS1zMN88US=> NH32dXk4OiCq MmrRSG1UVw>? MXXpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MXSyNlgzPjR4Nx?=
U937 NV7ObJc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYCw[pJmPS1{MDFOwG0> NXTNUlB2OjRxNEivO|IhcA>? NWq1W4h6cW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M4TySFIzPzZ5MEKx
HL60 MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnyTFFvPS1{MDFOwG0> M2qwe|I1NzR6L{eyJIg> NGXzNFlqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz Ml70NlI4PjdyMkG=
U937 NGq5bYhCeG:ydH;zbZMhSXO|YYm= MXSxOUDPxE1? NXnzUGFSOjRxNEivO|IhcA>? MYnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MWOyNlc3PzB{MR?=
HL60 M{DBXGFxd3C2b4Ppd{BCe3OjeR?= MnLmNVUh|ryP NHPZNIIzPC92OD:3NkBp MmW3bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NHzxZ3gzOjd4N{CyNS=>
LS411N  NGG4dWVCeG:ydH;zbZMhSXO|YYm= Moq4NE42KM7:TR?= M3zxS|czKGh? MlTibY5kemWjc3XzJGZieyCvUl7BJIxmfmWu MXWyNlQ3OTZ7NR?=
MDA-MB-231 NELDSWhCeG:ydH;zbZMhSXO|YYm= MnP5NVAh|ryP MX[0PEBp MYXy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlzENlE5QDd4OUe=
MCF-7  MkT4RZBweHSxc3nzJGF{e2G7 MUKxNEDPxE1? NVv4TG1EPDhiaB?= M{XHSpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUjj[2JyOjF6OEe2PVc>
A375 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ZNE42KM7:TR?= MXOxM|UwQCCm NYrxTHNtcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M2qxUFIyPzl4NkKy
SKMEL1 M{WxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrxd2NbOC53IN88US=> MWWxM|UwQCCm M2DyOolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NWjRdotWOjF5OU[2NlI>
SKMEL3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWCwMlUh|ryP M{HrdVEwPS96IHS= NHv0VoRqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MWWyNVc6PjZ{Mh?=
SKMEL28 NGm5TIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon1NE42KM7:TR?= Mn:4NU82NzhiZB?= MUHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NGeyfmIzOTd7Nk[yNi=>
MeWo MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjSWGcxNjVizszN M4PVPVEwPS96IHS= NGr3dHNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M1n3[VIyPzl4NkKy
B16 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF70ZXQxNjVizszN MV2xM|UwQCCm Ml3hbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NWLI[YM{OjF5OU[2NlI>
Ly 1 M1rNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPhXYQzPCCq Ml2yTWM2OD15LkOg{txO NHTRc|MzOTd5MkC0PS=>
Ly 7 NF7VTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XU[lI1KGh? MVzJR|UxRTFyLkeg{txO NITTNmUzOTd5MkC0PS=>
Su-DHL6 NWm0OFJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPUOpgzPCCq MWfJR|Ux97zgMkCg{txO MlHTNlE4PzJyNEm=
Ly 10 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWyOEBp NUXvNGV2UUN3MP-8olIxKM7:TR?= M2DTNlIyPzd{MES5
RIVA M{LrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTSNmxYOjRiaB?= NI\XSXJKSzVy78{eNlAh|ryP NH\1cYszOTd5MkC0PS=>
Su-DHL2 M4q3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLNNY0zPCCq NHe5fnlKSzVy78{eNlAh|ryP MWOyNVc4OjB2OR?=
Ly 1 NYntZ2QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITFeII1QCCq NXy3Vmp7UUN3ME2wMlM1KM7:TR?= MUGyNVc4OjB2OR?=
Ly 7 MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LVRVQ5KGh? M{TvTmlEPTB;MD6wNlUh|ryP MXGyNVc4OjB2OR?=
Su-DHL6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\YZ|Q5KGh? MmDvTWM2OO,:nkKwJO69VQ>? NEnNS5IzOTd5MkC0PS=>
Ly 10 NYe0W49pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT6R4k1QCCq M4jJVWlEPTB;MT64JO69VQ>? M4G1Z|IyPzd{MES5
RIVA Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHaV252PDhiaB?= NX3lNIZ7UUN3MP-8olIxKM7:TR?= M4rkNVIyPzd{MES5
Su-DHL2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO0PEBp NE[3fIRKSzVyPUG3MlQh|ryP M{m4elIyPzd{MES5
Ly 1 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUK3NkBp MknDTWM2OD1yLkCxJO69VQ>? M4rXTFIyPzd{MES5
Ly 7 M1XKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrYS3g4OiCq MVPJR|UxRTBwMEG4JO69VQ>? M{C3OFIyPzd{MES5
Su-DHL6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUW3NkBp MVPJR|UxRTFwNjFOwG0> M3jLclIyPzd{MES5
Ly 10 NUfVc21IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3xXW5FPzJiaB?= Mke3TWM2OD1zLkKg{txO MVuyNVc4OjB2OR?=
RIVA M{PNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO1c3o4OiCq NH76dHNKSzVy78{eNlAh|ryP NVnZVIZEOjF5N{KwOFk>
Su-DHL2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG4Xmc4OiCq NGHC[XdKSzVyPUGxMlIh|ryP NHLaVowzOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

体内研究 Decitabine 按2.5 mg/kg 剂量作用于ALK+ KARPAS-299小鼠移植瘤模型,促进凋亡,且降低肿瘤细胞增殖,也导致肿瘤抑制基因p16INK4A的去甲基化。 [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

DNA合成检测 :

通过测定放射性胸甘摄入到DNA的情况而测定DNA合成比率。HL-60 和KG1a 细胞悬浮在6孔(直径为35 mm )盘中,孔中为含10%胎牛血清的2 mL RPMI 培养基中,然后与不同浓度相应药物温育48小时 (药物同时加入)。48小时时, 每孔加入0.5 μCi [3H] 胸甘(6.7 Ci/mmol),再温育24小时。细胞置于GF/C玻璃纤维过滤器(直径为2.4 cm)中,使用冷 0.9% NaCl, 5% 冷三氯乙酸和乙醇清洗。烘干含DNA的过滤器,置于EcoLite闪烁液(ICN)中,使用 Beckman LS 6000IC 闪烁计数器测量放射性。通过剂量-反应曲线计算IC50值。
细胞实验:[1]
+ 展开
  • Cell lines: HL-60 和 KG1a
  • Concentrations: 0 到100 ng/mL
  • Incubation Time: 96 小时
  • Method: 生长抑制实验中,指数生长期细胞接种在5 ml培养基中。向培养基中同时加入不同浓度Decitabine。在指定时间,使用模型 ZM Coulter 计数器对细胞进行计数。根据药物处理的白血病细胞的生长曲线,测定IC50值。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: KARPAS-299 人类细胞皮下接种到小鼠的左右两侧。
  • Formulation: Decitabine 溶于无菌PBS
  • Dosages: ≤2.5 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 228.21
化学式

C8H12N4O4

CAS号 2353-33-5
稳定性 powder
in solvent
别名 Deoxycytidine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03828084 Not yet recruiting Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03828084 Not yet recruiting Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03844815 Not yet recruiting Acute Myeloid Leukemia University of Chicago|AbbVie April 10 2019 Phase 1
NCT03844815 Not yet recruiting Acute Myeloid Leukemia University of Chicago|AbbVie April 10 2019 Phase 1
NCT03875287 Not yet recruiting Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals March 2019 Phase 1
NCT03875287 Not yet recruiting Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals March 2019 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: 购买Decitabine | Decitabine供应商 | 采购Decitabine | Decitabine价格 | Decitabine生产 | 订购Decitabine | Decitabine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID